Floru L, Tegeler J
Arzneimittelforschung. 1978;28(2):341-4.
A pilot study with the new oral long-acting neuroleptic agent clopimozide, a diphenylbutylpiperidine derivative, has been reported. 30 female patients, only 20 of whom completed the trial, were treated with dosages of between 5 and 35 mg. The treatment comprised four periods in which the maximum tolerated daily dosage, the optimal weekly dosage (mean: 20.25 mg), the maximum tolerated weekly dosage and the optimal daily dosage were to be determined. In 10 patients plasma levels were determined with the radio-immunological method. The product exhibited a marked effect on schizophrenic target symptoms (significant at the 0.001 and 0.01 levels), of at least one week's duration, with an absence of sedation and a low degree of extrapyramidal side-effects. Clopimozide appears to be particularly suitable for the neuroleptic long-term treatment of compensated schizophrenic patients with insight into their disease.
一项关于新型口服长效抗精神病药物氯哌莫齐（一种二苯基丁基哌啶衍生物）的试点研究已有报道。30名女性患者接受了5至35毫克剂量的治疗，其中只有20名患者完成了试验。治疗包括四个阶段，在这些阶段中要确定最大耐受日剂量、最佳周剂量（平均：20.25毫克）、最大耐受周剂量和最佳日剂量。10名患者通过放射免疫法测定了血浆水平。该产品对精神分裂症的目标症状有显著效果（在0.001和0.01水平上具有显著性），持续时间至少为一周，无镇静作用且锥体外系副作用程度较低。氯哌莫齐似乎特别适合对有自知力的代偿性精神分裂症患者进行抗精神病药物的长期治疗。
